Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models

Journal of Immunotherapy

Volumn 31, Issue 3, 2008, Pages 235-245

  Sadun, Rebecca E ^a   Hsu, Wen En ^a   Zhang, Nan ^a   Nien, Yu Chih ^a   Bergfeld, Scott A ^a   Sabzevari, Helen ^c   Lutsiak, M E Christine ^c   Khawli, Leslie ^b   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody immunotherapy; CD134L; Fc mOX40L; Fusion proteins; OX40L; TNFSF

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 38; OX40 LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; GENETIC ENGINEERING; IN VITRO STUDY; LYMPHOID CELL; LYMPHOMA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR REGRESSION;

ANIMALS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OX40 LIGAND; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 41149174875     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816a88e0     Document Type: Article

References (52)

1. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. Embo J. 1990;9:1063-1068.
2. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, et al. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions. J Immunol. 1993;151:5261-5271.
3. Paterson DJ, Jefferies WA, Green JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987;24:1281-1290.
4. Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol. 1991;11:1313-1325.
5. + T cells with homology to tumor necrosis factor. J Exp Med. 1994;180:757-762.
6. Stuber E, Neurath M, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 1995;2:507-521.
7. Ohshima Y, Tanaka Y, Tozawa H, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159:3838-3848.
8. Weinberg AD, Wegmann KW, Funatake C, et al. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999;162:1818-1826.
9. Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996;183:2185-2195.
10. Pippig SD, Pena-Rossi C, Long J, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol. 1999;163:6520-6529.
11. Takasawa N, Ishii N, Higashimura N, et al. Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn J Cancer Res. 2001;92:377-382.
12. Soroosh P, Ine S, Sugamura K, et al. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol. 2006;176:5975-5987.
13. Gramaglia I, Jember A, Pippig SD, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165:3043-3050.
14. Maxwell JR, Weinberg A, Prell RA, et al. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol. 2000;164:107-112.
15. Gramaglia I, Weinberg AD, Lemon M, et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 1998;161:6510-6517.
16. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15:445-455.
17. Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med. 2000;191:365-374.
18. Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T cell stage. Semin Immunol. 1998;10:471-480.
19. Wang HC, Klein JR. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation. J Immunol. 2001;167:6717-6723.
20. Bansal-Pakala P, Halteman BS, Cheng MH, et al. Costimulation of CD8 T cell responses by OX40. J Immunol. 2004;172:4821-4825.
21. Serghides L, Bukczynski J, Wen T, et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol. 2005;175:6368-6377.
22. Fujita T, Ukyo N, Hori T, et al. Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett. 2006;106:27-33.
23. Ruby CE, Redmond WL, Haley D, et al. Anti-OX40 stimulation in vivo enhances CD4+ memory T cell survival and significantly increases recall responses. Eur J Immunol. 2007;37:157-166.
24. Maxwell JR, Yadav R, Rossi RJ, et al. IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway. J Immunol. 2006;177:234-245.
25. Gavin MA, Clarke SR, Negrou E, et al. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol. 2002;3:33-41.
26. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
27. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol. 2004;172:3580-3589.
28. Valzasina B, Guiducci C, Dislich H, et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105:2845-2851.
29. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164:2160-2169.
30. Lee SJ, Myers L, Muralimohan G, et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol. 2004;173:3002-3012.
31. Gri G, Gallo E, Di Carlo E, et al. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol. 2003;170:99-106.
32. Pan PY, Zang Y, Weber K, et al. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 2002;6:528-536.
33. Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004;64:3281-3287.
34. Kaneko H, Hori T, Yanagita S, et al. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo. Exp Hematol. 2005;33:336-343.
35. Zhang N, Sadun RE, Arias RS, et al. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007;13:2758-2767.
36. Morris NP, Peters C, Montler R, et al. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol. 2007;44:3112-3121.
37. Taylor L, Bachler M, Duncan I, et al. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions. J Leukoc Biol. 2002;72:522-529.
38. Li J, Hu P, Khawli LA, et al. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004;23:1-10.
39. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741-750.
40. Liu A, Hu P, Khawli LA, et al. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005;11:8492-8502.
41. Hu P, Arias RS, Sadun RE, et al. Construction and pre-clinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008;14:579-588.
42. + Tregs. Blood. 2007;110:2501-2510.
43. Ali SA, Ahmad M, Lynam J, et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine. 2004;22:3585-3594.
44. Weinberg AD, Thalhofer C, Morris N, et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother. 2006;29:575-585.
45. Li J, Hu P, Khawli LA, et al. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003;26:320-331.
46. Li J, Hu P, Khawli LA, et al. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003;63:8384-8392.
47. Karakousis CP, Rao U, Holtermann OA, et al. Tourniquet infusion chemotherapy in extremities with malignant lesions. Surg Gynecol Obstet. 1979;149:481-490.
48. Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep. 2007;9:109-114.
49. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806-813.
50. + T cell subsets. Nat Immunol. 2003;4:225-234.
51. Northrop JK, Shen H. CD8 T-cell memory: only the good ones last. Curr Opin Immnol. 2004;16:451-455.
52. Lee SW, Park Y, Song A, et al. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol. 2006;177:4464-4472.